Inmunoterapia en el cáncer de pulmón

  1. Casado, D. 1
  2. Bellido, L. 1
  3. Del Barco, E. 1
  4. Cigarral, B. 1
  5. Escalera, E. 1
  6. Claros, J. 1
  7. Barrios, B. 1
  8. Figuero, L. 1
  9. Olivares, A. 1
  10. López, A. 1
  11. Terán, E. 1
  12. Cruz, J.J. 1
  1. 1 Instituto de Investigación Biomédica de Salamanca (IBSAL), Servicio de Oncología Médica, Complejo Asistencial Universitario de Salamanca (CAUSA), Salamanca, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2021

Título del ejemplar: Enfermedades oncológicas (II)Tumores torácicos. Cáncer de cabeza y cuello

Serie: 13

Número: 25

Páginas: 1424-1428

Tipo: Artículo

DOI: 10.1016/J.MED.2021.02.009 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

La inmunoterapia es un tratamiento que devuelve al sistema inmune del paciente la capacidad de reconocer el tumor y luchar contra él. En la última década, han surgido multitud de ensayos clínicos con resultados favorables a la inmunoterapia, recibiendo nuevas indicaciones en diferentes tipos de tumores. El beneficio clínico y la buena tolerancia han hecho que la inmunoterapia se posicione en las primeras líneas terapéuticas del cáncer de pulmón. Sus principales indicaciones son el cáncer no microcítico de pulmón metastásico, tanto en primera línea, en monoterapia o en combinación con quimioterapia (dependiendo del PD-L1 expresado por el tumor), como en segunda línea (en monoterapia). También está aprobada en tumores localmente avanzados irresecables (tras quimiorradioterapia) y en el cáncer microcítico de pulmón diseminado.

Referencias bibliográficas

  • Choi SH, Chae EJ, Kim JE, Kim EY, Oh SY, Hwang HJ, et al. Percutaneous CT-guided aspiration and core biopsy of pulmonary nodules smaller than 1 cm: Analysis of outcomes of 305 procedures from a tertiary referral center. Am J Roentgenol [Internet]. 2013 Nov;201(5):964-70. Disponible en: https://pubmed.ncbi.nlm.nih.gov/24147465/
  • Fontaine-Delaruelle C, Souquet PJ, Gamondes D, Pradat E, De Leusse A, Ferretti GR, et al. Negative predictive value of transthoracic coreneedle biopsy: A multicenter study. Chest [Internet]. 2015 Aug 1;148(2):472-80. Disponible en: https://pubmed.ncbi.nlm.nih.gov/25569025/
  • Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fülöp A, et al. Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol [Internet]. 2019;37(7):537-46. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30620668/
  • Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Cso ̋ szi T, Fülöp A, et al. Pembrolizumab versus Chemotherapy for PD-L1–positive non-small-cell lung cancer. N Engl J Med [Internet]. 2016 Nov 10;375(19):1823-33. Disponible en: http://www.nejm.org/doi/10.1056/NEJMoa1606774
  • IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-lin | OncologyPRO [Internet]. Disponible en: https://oncologypro.esmo.org/meeting-resources/esmo-2019-congress/IMpower110-Interim-overall-survival-OS-analysis-of-a-phase-III-study-of-atezolizumab-atezo-vs-platinum-based-chemotherapy-chemo-as-first-line-1L-treatment-tx-in-PD-L1-selected-NSCLC
  • Burdett S, Burdett S, Stephens R, Stewart L, Tierney J, Auperin A, et al. Chemotherapy in addition to supportive care improves survival in advan-ced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials [Internet]. Vol. 26, Journal of Clinical Oncology. J Clin Oncol; 2008 p.4617-25. Disponible en: https://pubmed.ncbi.nlm.nih.gov/18678835/
  • Chemotherapy and supportive care versus supportive care alone for ad-vanced non-small cell lung cancer. Cochrane Database Syst Rev [Inter-net]. 2010 May 12;(5). Disponible en: https://pubmed.ncbi.nlm.nih.gov/20464750/
  • Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metasta-tic non–small-cell lung cancer. N Engl J Med [Internet]. 2018 May 31;378(22):2078-92. Disponible en: http://www.nejm.org/doi/10.1056/NEJMoa1801005
  • Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim S-W, Carcereny Costa E, et al. Nivolumab plus ipilimumab in advanced non–small-cell lung cancer. N Engl J Med [Internet]. 2019 Nov 21;381(21):2020-31. Disponible en: http://www.nejm.org/doi/10.1056/NEJMoa1910231
  • Paz-Ares L, Mezger J, Ciuleanu TE, Fischer JR, von Pawel J, Provencio M, et al. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INS-PIRE): An open-label, randomised, controlled phase 3 study. Lancet On-col [Internet]. 2015 Mar 1;16(3):328-37. Disponible en: https://pubmed.ncbi.nlm.nih.gov/25701171/
  • Paz-Ares L, Socinski MA, Shahidi J, Hozak RR, Soldatenkova V, Kurek R, et al. Correlation of EGFR-expression with safety and efficacy outco-mes in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer. Ann Oncol [Internet]. 2016 Aug 1;27(8):1573-9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27207107/
  • Mazieres J, Kowalski D, Luft A, Vicente D, Tafreshi A, Gümüs ̧ M, et al. Health-related quality of life with carboplatin-paclitaxel or nab-paclitaxel with or without pembrolizumab in patients with metastatic squamous non-small-cell lung cancer. J Clin Oncol [Internet]. 2020 Jan 20;38(3):271-80. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31751163/
  • Jotte RM, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Rodriguez Abreu D, Hussein MA, et al. IMpower131: Primary PFS and safety analy-sis of a randomized phase III study of atezolizumab + carboplatin + pacli-taxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. J Clin Oncol. 2018 Jun 20;36(18)Suppl:LBA9000.
  • Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Ste-phens RJ, et al. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE collaborative group. J Clin Oncol [Internet]. 2008;26(21):3552-9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/18506026/
  • Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, et al. The differential efficacy of pemetrexed according to nsclc histology: a review of two phase iii studies. Oncologist [Internet]. 2009 Mar Sep;14(3):253-63. Disponible en: https://pubmed.ncbi.nlm.nih.gov/19221167/
  • Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metas-tatic nonsquamous NSCLC. N Engl J Med [Internet]. 2018 Jun 14;378(24):2288-301. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29863955/
  • Reck M, Mok TSK, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med [Internet]. 2019 May 1;7(5):387-401. Disponible en: https://pubmed.ncbi.nlm.nih.gov/ 30922878/
  • West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol [In-ternet]. 2019 Jul 1;20(7):924-37. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31122901
  • Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med [Internet]. 2015 Jul;373(2):123-35. Disponible en: http://www.nejm.org/doi/10.1056/NEJMoa1504627
  • Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med [Internet]. 2015 Oct 22;373(17):1627-39. Disponible en: http://www.nejm.org/doi/10.1056/NEJMoa1507643
  • Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who comple-ted 2 years of pem | OncologyPRO [Internet]. Disponible en: https://oncologypro.esmo.org/meeting-resources/esmo-immuno-oncology-congress-2018/Long-term-follow-up-in-the-KEY-NOTE-010-study-of-pembrolizumab-pembro-for-advanced-NSCLC-including-in-patients-pts-who-completed-2-years-of-pembro-and-pts-who-received-a-second-course-of-pembro
  • Herbst R, Garon E, Kim D-W, Cho BC, Gadgeel S, Léna H, et al. OA03.07 KEYNOTE-010: durable clinical benefit in patients with pre-viously treated, PD-L1-expressing NSCLC who completed pembrolizu-mab. J Thorac Oncol [Internet]. 2017 Jan 1;12(1):S254-5. Disponible en: http://www.jto.org/article/S155608 6416314848/fulltext
  • Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet [Internet]. 2017 Jan 21;389(10066):255-65. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27979383/
  • Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in pa-tients with previously treated non-small-cell lung cancer (LUME-Lung 1): A phase 3, double-blind, randomised controlled trial. Lancet Oncol [Internet]. 2014 Feb;15(2):143-55. Disponible en: https://pubmed.ncbi.nlm.nih.gov/24411639/
  • Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for se-cond-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, dou-ble-blind, randomised phase 3 trial. Lancet [Internet]. 2014;384(9944):665-73. Disponible en: https://pubmed.ncbi.nlm.nih.gov/24933332/
  • Cortot AB, Audigier-Valette C, Molinier O, Le Moulec S, Barlesi F, Zalcman G, et al. Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non–small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study. Eur J Cancer [Internet]. 2020 May 1;131:27-36. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32276179/
  • EMA recommends extension of indications for durvalumab [In-ternet]. Disponible en: https://www.esmo.org/oncology-news/ema-recommends-extension-of-indica-tions-for-durvalumab
  • Aisner DL, Akerley W, Bauman JR, Bruno DS, Chang JY, Chirieac LR, et al. Continue NCCN Guidelines Panel Disclosures NCCN Guidelines Version 8.2020 Non-Small Cell Lung Cancer. 2020.
  • Informe SEOM de evaluación de fármacos.
  • Horn L, Mansfield AS, Szcze ̨sna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med [Internet]. 2018 Dec 6;379(23):2220-9. Disponible en: http://www.nejm.org/doi/10.1056/NEJMoa1809064
  • IMpower133: updated overall survival (OS) analysis of first-line (1L) ate-zolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC) | OncologyPRO [Internet]. Disponible en:https://oncologypro.esmo.org/meeting-resources/esmo-2019-congress/IMpower133-updated-overall-survival-OS-analysis-of-first-line-1L-atezolizumab-atezo-carboplatin-etoposide-in-extensive-stage-SCLC-ES-SCLC
  • Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet [Internet]. 2019 Nov 23;394(10212):1929-39. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31590988/
  • Dominé M, Moran T, Isla D, Martí JL, Sullivan I, Provencio M, et al. SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019). Clin Transl Oncol. 2020;22(2):245-55. doi:10.1007/s12094-020-02295-w
  • Majem M, Juan O, Insa A, Reguart N, Trigo JM, Carcereny E, et al. SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). Clin Transl Oncol. 2019;21(1):3-17. doi:10.1007/s12094-018-1978-1
  • Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg [Internet]. 2011 Jul;128(1):305-10. Disponible en: /pmc/articles/PMC3124652/?report=abstrac
Fuente de los datos: Dialnet